Stock Analysis
A Look At The Intrinsic Value Of Sunflower Pharmaceutical Group Co.,Ltd (SZSE:002737)
Key Insights
- The projected fair value for Sunflower Pharmaceutical GroupLtd is CN¥22.97 based on 2 Stage Free Cash Flow to Equity
- Sunflower Pharmaceutical GroupLtd's CN¥21.60 share price indicates it is trading at similar levels as its fair value estimate
- Sunflower Pharmaceutical GroupLtd's peers are currently trading at a premium of 97% on average
Does the August share price for Sunflower Pharmaceutical Group Co.,Ltd (SZSE:002737) reflect what it's really worth? Today, we will estimate the stock's intrinsic value by projecting its future cash flows and then discounting them to today's value. The Discounted Cash Flow (DCF) model is the tool we will apply to do this. Believe it or not, it's not too difficult to follow, as you'll see from our example!
We would caution that there are many ways of valuing a company and, like the DCF, each technique has advantages and disadvantages in certain scenarios. For those who are keen learners of equity analysis, the Simply Wall St analysis model here may be something of interest to you.
View our latest analysis for Sunflower Pharmaceutical GroupLtd
The Method
We are going to use a two-stage DCF model, which, as the name states, takes into account two stages of growth. The first stage is generally a higher growth period which levels off heading towards the terminal value, captured in the second 'steady growth' period. To begin with, we have to get estimates of the next ten years of cash flows. Seeing as no analyst estimates of free cash flow are available to us, we have extrapolate the previous free cash flow (FCF) from the company's last reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years.
A DCF is all about the idea that a dollar in the future is less valuable than a dollar today, so we need to discount the sum of these future cash flows to arrive at a present value estimate:
10-year free cash flow (FCF) estimate
2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 | |
Levered FCF (CN¥, Millions) | CN¥653.1m | CN¥625.4m | CN¥612.2m | CN¥608.4m | CN¥610.9m | CN¥617.9m | CN¥628.2m | CN¥640.8m | CN¥655.4m | CN¥671.4m |
Growth Rate Estimate Source | Est @ -7.28% | Est @ -4.24% | Est @ -2.11% | Est @ -0.62% | Est @ 0.42% | Est @ 1.15% | Est @ 1.66% | Est @ 2.02% | Est @ 2.27% | Est @ 2.44% |
Present Value (CN¥, Millions) Discounted @ 6.8% | CN¥611 | CN¥548 | CN¥502 | CN¥467 | CN¥439 | CN¥416 | CN¥395 | CN¥378 | CN¥361 | CN¥347 |
("Est" = FCF growth rate estimated by Simply Wall St)
Present Value of 10-year Cash Flow (PVCF) = CN¥4.5b
The second stage is also known as Terminal Value, this is the business's cash flow after the first stage. The Gordon Growth formula is used to calculate Terminal Value at a future annual growth rate equal to the 5-year average of the 10-year government bond yield of 2.9%. We discount the terminal cash flows to today's value at a cost of equity of 6.8%.
Terminal Value (TV)= FCF2034 × (1 + g) ÷ (r – g) = CN¥671m× (1 + 2.9%) ÷ (6.8%– 2.9%) = CN¥17b
Present Value of Terminal Value (PVTV)= TV / (1 + r)10= CN¥17b÷ ( 1 + 6.8%)10= CN¥8.9b
The total value, or equity value, is then the sum of the present value of the future cash flows, which in this case is CN¥13b. To get the intrinsic value per share, we divide this by the total number of shares outstanding. Compared to the current share price of CN¥21.6, the company appears about fair value at a 6.0% discount to where the stock price trades currently. Remember though, that this is just an approximate valuation, and like any complex formula - garbage in, garbage out.
Important Assumptions
We would point out that the most important inputs to a discounted cash flow are the discount rate and of course the actual cash flows. If you don't agree with these result, have a go at the calculation yourself and play with the assumptions. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at Sunflower Pharmaceutical GroupLtd as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 6.8%, which is based on a levered beta of 0.800. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.
SWOT Analysis for Sunflower Pharmaceutical GroupLtd
- Debt is not viewed as a risk.
- Dividend is in the top 25% of dividend payers in the market.
- Earnings declined over the past year.
- Current share price is below our estimate of fair value.
- Lack of analyst coverage makes it difficult to determine 002737's earnings prospects.
- Dividends are not covered by earnings and cashflows.
Looking Ahead:
Although the valuation of a company is important, it is only one of many factors that you need to assess for a company. The DCF model is not a perfect stock valuation tool. Preferably you'd apply different cases and assumptions and see how they would impact the company's valuation. For instance, if the terminal value growth rate is adjusted slightly, it can dramatically alter the overall result. For Sunflower Pharmaceutical GroupLtd, we've compiled three essential elements you should consider:
- Risks: Case in point, we've spotted 1 warning sign for Sunflower Pharmaceutical GroupLtd you should be aware of.
- Other Solid Businesses: Low debt, high returns on equity and good past performance are fundamental to a strong business. Why not explore our interactive list of stocks with solid business fundamentals to see if there are other companies you may not have considered!
- Other Top Analyst Picks: Interested to see what the analysts are thinking? Take a look at our interactive list of analysts' top stock picks to find out what they feel might have an attractive future outlook!
PS. The Simply Wall St app conducts a discounted cash flow valuation for every stock on the SZSE every day. If you want to find the calculation for other stocks just search here.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About SZSE:002737
Sunflower Pharmaceutical GroupLtd
Engages in the research and development, manufacturing, and marketing of Chinese patent medicines in China and internationally.